Business Wire

FISHAWACK-HEALTH

8.4.2020 21:17:05 CEST | Business Wire | Press release

Share
Fishawack Health Adds Market Access and Commercial Strategy Consultancy Skysis as Part of Its Bold Growth Plans

Fishawack Health , the global healthcare communications agency, announces the acquisition of Skysis , a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005692/en/

Skysis expertise bolsters Fishawack Health’s impressive consulting capabilities. The company brings with it the ability to connect interdependencies across healthcare professional (HCP), payer, channel, and patient stakeholders. It is the first acquisition with Fishawack Health’s new investor, Bridgepoint.

Oliver Dennis , Fishawack Health co-founder and CEO, said: “In partnering with Bridgepoint, we have made a step-change in our ambition. We’re delighted today to add Skysis to the group. They bring strategy and market access across the entire commercial life cycle, making them an important addition to our strategic consulting capabilities.”

Fred Bassett , Head of Consulting for Fishawack Health, added: “Skysis provides strategy and execution across every stage of the commercial life cycle. The company’s expertise bolsters Fishawack Health’s strong strategic consulting team, which includes analysts, researchers, commercial consultants, market access and customer experience specialists, and boasts a network of Physician Expert Partnerships.”

Providing further detail, Dan Twibell , Managing Director of Skysis, explained: “We wanted to partner with a group that could help us scale our business, offer more solutions to our clients and that our team would be excited to join.”

Dawn Rich , Managing Director of Skysis, said: “Our team is thrilled to be joining Fishawack Health. Our core capabilities match perfectly with the key services of the wider consulting capability.”

Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties identifying that Skysis’ four core practice areas – market access, new product planning /launch excellence, market insights, brand management and engagement – were a perfect match with Fishawack Health’s capabilities.

Established in 2001, Fishawack Health has become one of the largest independent healthcare communications organisations in the world. It has 14 offices across Europe and the US, and a highly skilled workforce of 850 employees. It serves more than 100 customers across 300 different drug compounds, including the top 20 global pharmaceutical companies and a range of innovative biotech and medical device companies.

Its three areas of specialism – strategic consulting and market access, medical communications, and commercial and creative execution – are underpinned by shared world-class resources. This includes digital expertise, insight, data analytics and visualisation, and media and production capabilities. These capabilities work independently or combine seamlessly as one unit, complete with teams tailored to the client’s individual needs and challenges.

Fishawack Health’s strategic and scientific focus makes it ideally placed to solve complex brand, portfolio, and enterprise-level challenges for its clients.

With experience across every major therapeutic category, Fishawack Health understands what it takes to improve patient outcomes and drive business success for its clients. The company will continue to add new capabilities designed to solve its clients’ critical medical and commercial challenges in an integrated and seamless way.

About Fishawack Health

Fishawack Health is an independent, full-service, global healthcare communications group with over 850 medical experts, marketing professionals, and strategic specialists. The organisation has three areas of specialism that work independently or as a single united team – strategic consulting and market access, medical communications, and commercial/creative execution.

About Skysis

Skysis is a boutique consulting firm that provides integrated commercial solutions to the biopharmaceutical industry. The organisation leverages their deep industry experience to generate insights and approaches that address their clients’ unique commercial needs.

Advisers involved in this transaction included:

KPMG Manchester acted on behalf of Fishawack Health for corporate finance and financial & tax due diligence; Addleshaw Goddard, Manchester and Sheppard Mullin, San Diego provided legal support. KPMG, Fairmount Partners, a leading investment bank focused on pharmaceutical services businesses, introduced the parties and acted as financial advisor to Skysis. Ulber & Berne LLP provided legal support.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye